Bio-Rad Labs (NYSE: BIO) reported Q2 EPS of $2.62, $0.81 better than the analyst estimate of $1.81. Revenue for the quarter came in at $651 million versus the consensus estimate of $623.89 million.

Full-Year 2026 Financial Outlook

For the full-year 2026, the Company continues to expect non-GAAP, currency-neutral revenue to be in the range of a decline of approximately 3.0 percent to growth of approximately 0.5 percent, and an estimated non-GAAP operating margin of approximately 10.0 to 12.0 percent.

For earnings history and earnings-related data on Bio-Rad Labs (BIO) click here.